Diabetes mellitus has reached epidemic proportions worldwide. In the United States, approximately 30% of Americans older than 60 years have type 2 diabetes mellitus (T2DM) or impaired fasting glucose (IFG). The prevalence of T2DM now shows a 30% increase in people aged 50 to 59 years, a 40% increase among those between the ages of 40 to 49 years, and a 70% increase in those 20 to 39 years old. During the past decade, the incidence of T2DM is thought to have increased more than 300% in children between the ages of 8 and 19 years. Note that the greatest rates of increase are in the young. The cardiovascular and microvascular complications of diabetes are well known to all physicians. Are we ready to treat teenagers with anterior wall myocardial infarctions?

How and when should we intervene when a person is at risk for diabetes? Major studies to date indicate that diabetes can be prevented with education, nutrition, and exercise. Results from the Diabetes Prevention Program,4 the Diabetes Prevention Study,5 Da Qing,6 and the Diabetes Epidemiology: Collaborative Analysis Of Diagnostic criteria in Europe (DECODE)7 all showed that prevention works. In fact, diet and exercise were more effective than medications. When does prevention begin?

Prevention and Early Intervention

The American Diabetes Association recommends starting a prevention program when the fasting plasma glucose (FPG) level is 110 mg/dL or if the individual has a first-degree relative with T2DM or has a body mass index greater than 25.8,9 Some endocrinologists consider starting a prevention program when the plasma glucose is greater than 95 mg/dL. In the future, we may consider a plasma glucose value of 95 mg/dL as being abnormal. Haffner’s studies in the 1990s10,11 suggested that heart disease begins 10 to 20 years before diabetes is formally diagnosed. The implication is clear: Interventions should begin well before diabetes is diagnosed.

If interventions should begin before diabetes is diagnosed, should we consider giving patients oral hypoglycemic agents for plasma glucose levels of less than 126 mg/dL? The answer is no. There are no clinical data to support the use of oral hypoglycemic agents for patients who have IFG. Also, there is no indication to use oral agents for patients with impaired glucose tolerance (glucose levels of less than 200 mg/dL 2 hours after a 75-g oral glucose challenge). However, thoughts on drug interventions are changing rapidly. It appears likely that recommendations may be forthcoming to consider using metformin, orlistat, or acarbose for people with impaired glucose tolerance or IFG.8

Clinical trials are in progress evaluating whether sulfonylureas, metformin, the thiazolidinediones, or combination oral modes of therapy would be beneficial. It is not known if early interventions with oral medications will reverse early changes in glucose metabolism or prevent their progression to T2DM. Hence, the oral agents are not approved by the Food and Drug Administration (FDA) for patients with plasma glucose levels of less than 126 mg/dL.

If T2DM is diagnosed, early and aggressive intervention is indicated. New recommendations for initiation of therapy for patients with T2DM are shown in Figure 1. The algorithm in Figure 1 is from the Texas Diabetes Council.12 It has been reviewed widely in the United States and has achieved much acceptance throughout the country. This algorithm is used if a person has an FPG level that is less than 260 mg/dL and is asymptomatic. Targets for therapeutic interventions are shown in the upper left box. Ranges are indicated for A1c,
A person requires insulin injections if a person requires insulin injections. Local tissue forms a large complex that slowly dis- solves into available insulin. Local tissue pH is approximately 7 and glargine is released from the injection site at a different rate in some patients. Insulin glargine is packaged at a pH of approximately 4. At the injection site, the glargine is released from the injection site at a different rate in some patients. It is possible that insulin glargine is released from the injection site at a different rate in some patients. Regardless of when insulin glargine is used, fasting glucose values are used to adjust the dose. Fasting glucose reflects basal insulin requirements. Glargine is a true long-acting insulin. It has no pronounced peak of metabolic activity. After subcutaneous injection, there is a slow constant release of insulin over approximately 24 hours. Most patients will inject insulin glargine at bedtime; however, it can be taken in the morning or in the evening as long as it is taken the same time each day. Regardless of whether insulin glargine is taken one or two A1C cycles to achieve glycemic goals. The American Diabetes Association guidelines (ADA) recommend that the fasting glucose level is 100 mg/dL to 120 mg/dL. If glargine is taken in the morning or the evening, the dose is adjusted to achieve morning self-monitored blood glucose levels of less than 100 mg/dL to 120 mg/dL. If glargine is taken at bedtime, the dose is adjusted to achieve morning self-monitored blood glucose levels of less than 100 mg/dL to 120 mg/dL. If glargine is taken in the morning or the evening, the dose is adjusted based on the self-monitored blood glucose level of the following morning.

Multiple Doses of Insulin

Health care providers should instruct patients on how to titrate insulin every 2 to 3 days. Advancing from once-a-day insulin use to multiple injections is done within 6 to 12 weeks. If patients advance to multiple doses of insulin, or start on a multidose regimen, the doses will be higher but the titration scheme is the same as for once-a-day insulin use. Patients will need to advance to intensive or physiologic insulin delivery if the glucose level is not controlled within 3 to 6 months.

Intensive Insulin Therapy

Intensive or physiologic insulin delivery can be achieved using continuous subcutaneous insulin infusion (insulin pump) or the new, 24-hour, basal insulin glargine in combination with the fast-acting human analogs insulin lispro or insulin aspart for bolus insulin requirements. Glargine is a true long-acting insulin. It has no pronounced peak of metabolic activity. After subcutaneous injection, there is a slow constant release of insulin over approximately 24 hours. Most patients will inject insulin glargine at bedtime; however, it can be taken in the morning or in the evening as long as it is taken the same time each day. Regardless of whether insulin glargine is used, fasting glucose values are used to adjust the dose. Fasting glucose reflects basal insulin requirements, and glargine is a basal insulin. If glargine is taken at bedtime, the dose is adjusted to achieve morning self-monitored blood glucose levels of less than 100 mg/dL to 120 mg/dL. If glargine is taken in the morning or the evening, the dose is adjusted based on the self-monitored blood glucose level of the following morning.

Occasionally (less than 10% of patients), mid-morning hypoglycemia may occur. In these instances, insulin glargine is given in the morning and the problem is avoided because the person usually eats three meals per day. The cause of mid-morning hypoglycemia is unknown. It is possible that insulin glargine is released from the injection site at a different rate in some patients. Insulin glargine is packaged at a pH of approximately 4. At the injection site, the tissue pH is approximately 7 and glargine forms a large complex that slowly dissociates into available insulin. Local tissue

Initiating Treatment With Combination Therapy

Many clinicians use combination therapy as the initial therapy, especially in the asymptomatic patient with glucose levels of greater than 210 mg/dL or an A1C value that is greater than 9.0%. If the patient is on monotherapy, glycemic targets should be reached within 3 months; if not, combination therapy is indicated. If the patient starts on combination therapy, glycemic targets should be reached within 3 to 6 months. If the patient is not at goal by 6 months, insulin is recommended.

It is important to realize that oral therapy should be started in patients with diabetes if the FPG level is 110 mg/dL to 130 mg/dL, or the patient’s glucose records indicate that the fasting glucose level is 100 mg/dL to 120 mg/dL. Therapeutic interventions should be advanced within one or two A1C cycles to achieve glycemic goals. The same recommendations hold for T2DM in children. Note that metformin is the only oral diabetic agent approved by the FDA for children aged 10 years and older; however, other oral agents may be used at the discretion of the clinician.

Insulin Therapy

Insulin therapy is indicated in patients who have not achieved control (A1c <6.5% to 7.0%; FPG <110 mg/dL to 130 mg/dL) using combination oral hypoglycemic agents after 3 to 6 months. When initiating insulin therapy, do not stop any of the oral agents. If the patient is taking an insulin sensitizer(s), it should be continued. In fact, sensitizers are indicated in patients with T2DM using 2 units of insulin per kilogram of body weight, or more than 100 units of insulin per day. The role of insulin secretagogues (sulfonylureas and meglitinides) is less clear. Common experience suggests that the sulfonylurea or repaglinide/nateglinide should be continued at least 3 to 6 months. When glycemic control is established, decisions can be made about weaning the patient off the secretagogue. Over time, it is difficult to argue that a person requires insulin injections and drugs to induce release of endogenous insulin.

Insulin therapy is indicated for treat- ment naive patients if their initial glucose level is greater than 260 mg/dL and they are symptomatic.

Both a basal and a short-acting insulin are indicated for patients with type 1 diabetes mellitus (T1DM). Oral agents are not used in patients with T1DM. Even though as many as 25% of patients with T1DM are overweight and insulin resis- tant, the insulin-sensitizing drugs (met- formin and the TZDs) have no role based on available data. Studies are actively looking at this issue.

Recommendations for insulin use have been codified in Figure 2. There are three basic options for the use of insulin. The regimen selected depends on clinical judgment and the patient’s wishes. Regimens include:

- once-a-day injections,
- multiple doses of insulin, or
- intensive insulin therapy.

Once-a-day Insulin Injections

Some patients with T2DM can be man- aged with one or two insulin injections per day. As diabetes progresses, how- ever, and the patient’s ability to produce endogenous insulin degenerates, intensive insulin therapy will be needed. The decision to advance an insulin regimen is dictated by whether glycemic goals are achieved within the time frames indicated. Important information on start- ing doses of insulin and how to titrate them are shown in the algorithm in Figure 2.
Figure 1. [Revision available at: http://www.dshs.state.tx.us/diabetes/PDF/algorithms/PHARM2.PDF]

GLYCEMIC CONTROL ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN¹ AND ADULTS

Targets
A1c <6.5-7.0% (<0.5-1.0% above reference range)
Fasting SMBG <100-120 mg/dL
2-hr PPG <140-180 mg/dL

Initial Intervention²

Education/Nutrition/Exercise ⁵

Targets Met
A1c every 3-6 months

FPG/SMBG/PPG Targets
Not Met After 1 Month

Consider Initial Monotherapy (or Early Dual Therapy ⁶)
Sulfonylurea and/or Metformin ¹⁻⁷

Targets Met
Continue Therapy
A1c every 3-6 months

Targets Not Met After 3 Months
Combine Sulfonylurea-Metformin

Other Initial Monotherapy Options:
Pioglitazone/Rosiglitazone
Nateglinide
Repaglinide
Acarbose/Miglitol
Insulin or Insulin Analog²

Other Combination Options:
Metformin or a Sulfonylurea plus
Pioglitazone/Rosiglitazone
or Acarbose/Miglitol
Metformin plus
Nateglinide or Repaglinide; or
Insulin or Insulin Analog (as mono-
or combination therapy)³

Targets Met
Continue Combination Therapy
A1c every 3-6 months

Targets Not Met After 3-6 Months
Add intermediate bedtime insulin or glargine;
before supper intermediate-regular insulin or lispro/
aspart mix; add third oral agent; or switch to split dose
insulin or insulin analog therapy⁵; consider referral to
dermatologist

¹. Metformin is the only FDA-approved oral diabetic agent in children (≥ age 10); other oral agents may be used
    at the discretion of the clinician
². See Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
³. If initial presentation with FPG ≥200 mg/dL in a symptomatic patient, consider insulin or insulin analog as initial intervention.
⁴. If initial FPG ≥210 mg/dL, or A1C ≥9.0%, consider dual oral agent therapy (metformin-sulfonylureas or other options) at presentation.
⁵. See Medical Nutrition and Exercise Algorithms
⁶. If initial dual oral therapy is initiated, consider on add-on therapy options within 3–6 months if glycemic targets are not met.
⁷. Preferred in overweight/obese or dyslipidemic patients.

Publication # 45-11265
See web site (http://www.tdh.state.tx.us/diabetes/idc.htm) for latest version.
Figure 2. [Revision available at: http://www.dshs.state.tx.us/diabetes/PDF/algorithms/INST2.pdf]
differences between patients may explain why some react differently to a given dose of insulin glargine.

It is unusual to use split-dose insulin glargine regimens. It is believed that less than 2% to 3% of patients with T1DM have less than 24-hour basal coverage. An important point to remember when using insulin glargine and lispro or aspart is to maintain about 50% to 60% basal insulin and 50% to 40% bolus insulin per day. It is very easy “to become upside-down” when making insulin adjustments based on glucose records. Often, a health care worker will increase the preprandial bolus insulin because glucose values at noon, evening, or bedtime are elevated and after 1 week, glycemic control deteriorates even further. Remember to “step back” and be certain that the proper ratios of basal-to-bolus insulin are used. If control is still not achieved, then it is time for the patient to work with the diabetes educator again on nutrition and lifestyle management.

The starting dose for intensive insulin therapy is indicated in the algorithm in Figure 2.14 For example, if a person weighs 100 kg, about 30 units to 50 units of insulin will be needed per day. Approximately one half of the amount would be given as basal insulin, and one half would be given as bolus insulin divided before meals.

The “rule of 1800” (1500 for regular insulin) is used to determine an augmentation dose of bolus insulin to cover high glucose values before meals. For example, if a person used approximately 50 units of insulin per day, the rule predicts that 1 unit of insulin will reduce the blood glucose level by about 36 mg/dL (1800 divided by 50 equals 36). Many clinicians instruct patients to use an augmentation dose in addition to the bolus dose if the blood glucose level is greater than 120 mg/dL before meals. In the example given here, the patient would take about 8 units of bolus insulin before eating and an additional 1 unit of bolus insulin for every 36 mg/dL that the blood glucose level is greater than 120 mg/dL.

Intensive insulin therapy with glargine and lispro or aspart offers advantages over the older insulin regimens based on intermediate- and short-acting insulin. The intermediate-acting insulins (isophane insulin suspension, insulin zinc suspension, and extended insulin zinc suspension) cannot achieve a steady basal state because these insulin preparations have peaks of activity. Recent data using continuous glucose monitoring sensors for more than 6 months on a group of pediatric patients with T1DM taking isophane insulin suspension revealed that glucose values of less than 40 mg/dL occurred on 27% of the nights. Glucose values less than 50 mg/dL occurred on 35% of the nights. In fact, to achieve ADA goals of fasting blood glucose values of less than 120 mg/dL, 100% of patients had glucose values of less than 60 mg/dL at some time during the night.15 Thus, to achieve ADA goals for fasting blood glucose values, all patients are sentenced to early morning hypoglycemia. A strong argument can be made to use the basal insulin glargine because it has no pronounced peak metabolic activity and hypoglycemia is less common. The short-acting regular insulin has some definite limitations. Its peak of activity occurs at 3 to 4 hours, which is at least 1 to 2 hours after postprandial glucose spikes.

**Postprandial Glucose Control**

Control of postprandial glucose is believed to be important. Data from several studies including the Funagata Diabetes Study,16 the Diabetes Intervention Study,17 the Whitehall and Paris Perspective,18 and the DECODE19 suggest that postprandial glycemic excursions are an independent risk factor for death after a myocardial infarction. Further, there exist data to show that FPG and A1c measurements do not accurately reflect total glycemic control. The Third National Health and Nutrition Examination Survey (NHANES III) reported that of patients with an A1c of less than 6.0%, 67% had postprandial glucose values greater than 200 mg/dL, and the average glycemic excursion was 208 mg/dL. The average A1c value of patients with T2DM in the United States is about 8.0% to 9.0%. Of these patients, 100% have postprandial excursions greater than 200 mg/dL and the average 2-hour postprandial value is 371 mg/dL.20 These extreme glycemic excursions and the data suggesting their relationship with post myocardial infarction death suggest that the fast-acting human analogs should be used because their rapid onset of activity coincides with the rise in postprandial glucose level.

Intensive insulin therapy tends to mimic physiologic insulin delivery. To explain this, let us consider where blood glucose derives from and how it is disposed of in normal physiology. Blood glucose has two main sources. Production of hepatic glucose, which supplies blood glucose during the fasting state, is constant. The gut absorbs glucose during the fed state. Basal insulin from the pancreatic beta cells disposes of hepatic glucose production into peripheral tissues while fasting.

Bolus insulin production actually occurs in two phases: the first phase occurs within several minutes of eating. It is a short, rapid burst of insulin that circulates directly to the liver. The first-phase insulin response is a signal that turns off hepatic glucose production. The second phase occurs about 15 minutes after beginning to eat and tapers back to baseline levels within 1 to 2 hours. The second-phase insulin response regulates glucose disposal into peripheral tissues during the fed state. One of the earliest changes that occurs in the prediabetic state is the loss of the first-phase insulin response. Patients with fasting glucose values between 100 mg/dL and 114 mg/dL have lost 50% of the first-phase response. Patients with glucose levels greater than 115 mg/dL have essentially no first-phase response and are similar to those who have T2DM.

An absent first-phase insulin response, an insufficient second-phase insulin response, and low basal insulin production partially explain why patients with diabetes have high blood glucose levels. They cannot dispose of basal glucose when fasting, and they receive a “double whammy” (gut and liver glucose) when eating. The purpose of using insulin glargine and fast-acting human insulin analogs is to address the basal and bolus insulin defects in diabetes. Hepatic glucose production is essentially constant, so a basal insulin with constant activity is required to regulate basal glucose.

Insulin glargine delivers usable insulin in an extremely linear fashion and appears to be almost as good as an insulin pump. It closely mimics physiologic basal
insulin in the normal state. Insulin lispro and insulin aspart have an onset of action that is detectable within 3 to 5 minutes. These very fast-acting insulins almost approximate a first-phase response to shut off hepatic glucose production. Their short duration is similar to the normal second-phase insulin response. Thus, the kinetics of these insulins explains why glargine is used once a day and lispro and aspart are used before meals.

Patients may be reluctant to start therapy with these newer insulins because they require four injections a day. Acceptance becomes a minor issue, however, when patients realize the lifestyle flexibility that these insulins afford and the degree of glycemic control that can be achieved with less hypoglycemia. Insulin glargine can be administered anytime as long as it is the same time each day. No lifestyle adjustments are needed between the weekdays and the weekends, and rotating workshifts present no problems. The timing of meals is no longer dictated by the 4- and 8-hour peaks of short- and intermediate-acting insulins.

Comment

It is interesting to look back over the decades of insulin management of diabetes. When regular insulin was the only type available, patients routinely used four to six injections per day. One could argue that the introduction of intermediate-acting insulins and the fixed-mix preparations in the 1950s was a great step backward. It allowed patients to survive on two injections a day, but at the expense of poor glycemic control and extreme glycemic excursions.

The new recombinant basal and bolus insulins offer much. Allergic reactions are rare, hypoglycemia is less common, the postprandial glucose level is controlled, and A1c measurements of 5.0% to 6.0% are expected and routinely attained.

References


